“Historically in the field, people have tried to overcome individual strategies that tumors use to evade immunotherapies.

as well as primary tumors. In addition to establishing the safety of the vector-transduced CAR-M cells administered intravenously, the phase 1 study will incorporate readouts to validate all ...

Physician-researchers with City of Hope have developed a way to add features to T cells to help them overcome mechanisms of ...

TCA-101 is under clinical development by TCR Cure Biopharma Technology and currently in Phase II for Solid Tumor.

Experiments using a coronavirus vector-based immunotherapy model further revealed that inducing FRC-supported tertiary lymphoid structures enhanced immune cell infiltration and anti-tumor activity.

CAR T cell therapy has revolutionized cancer care, providing a powerful option ... due to limited DNA packaging capacity of current vector systems,” said Scott E. James, M.D., Ph.D., assistant ...

Overall, this fundamental study identified a novel role of NOLC1 in regulating p53 nuclear transcriptional activity and p53-mediated ferroptosis in gastric cancer. The evidence supporting the ...

Mu-28ZT2 is under clinical development by Wellington Zhaotai Therapies and currently in Phase I for Lung Cancer.

Cancer immunotherapy relies on modified ... T cells from the patient through apheresis and using a viral vector to modify the ...